Nanoviricides, Inc. insider trading

Every open-market purchase and sale by Nanoviricides, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Nanoviricides, Inc.’s insiders pay?

From June 25, 2010 to November 17, 2015, 5 insiders reported 22 open-market purchases and 42 sales not made under a pre-set plan in Nanoviricides, Inc. After sales, the shares moved −50.3% against the index over 12 months (a negative figure means selling was the right call).

Nanoviricides, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Diwan Anil	President	4	—	—	40	−50.3% (1)	January 13, 2015
Boniuk Milton	Director	16	—	—	0	—	November 17, 2015
Theracour Pharma, Inc.	10% owner	0	—	—	2	—	February 1, 2013
Seymour Eugene	Chief Executive Officer	1	—	—	0	—	March 11, 2013
Vyas Meeta	Chief Financial Officer	1	—	—	0	—	September 8, 2014

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Nanoviricides, Inc. · Funds · Politicians